Table 5.

Sensitivity analysis showing vital status and multivariate models at 1-, 2-, and 3-year landmark time points excluding patients who did not receive bDMARDs until the respective landmark time points

Vital status at landmark time points by bDMARD use	1 year landmark		2 year landmark		3 year landmark
	Alive/censored	Death	Alive/censored	Death	Alive/censored	Death
No bDMARD	185	80	169	56	146	40
TNFi	49	10	43	9	35	6
Non-TNFi	3	0	3	0	3	0
Multivariate models
	HR	95% CI	HR	95% CI	HR	95% CI
Age at cancer diagnosis	1.03	1.00–1.06	1.05	1.01–1.09	1.10	1.04–1.16
bDMARD use
No bDMARD	Ref		Ref		Ref
TNFi or Non-TNFi	0.57	0.21–1.54	1.02	0.35–3.02	1.24	0.35–4.33

Abbreviations: HR, Hazard ratio; CI, confidence interval; bDMARD biologic disease-modifying anti-rheumatic drugs; TNFi, tumor necrosis factor inhibitors; non-TNFi, non-tumor necrosis factor inhibitors